| scholarly article | Q13442814 |
| P2093 | author name string | S. J. Pocock | |
| K. F. Kerrebijn | |||
| van Essen-Zandvliet EE | |||
| M. D. Hughes | |||
| E. J. Duiverman | |||
| E. E. van Essen-Zandvliet | |||
| H. J. Waalkens | |||
| P2860 | cites work | Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma | Q28328440 |
| Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study | Q35181695 | ||
| Bronchial responsiveness to histamine: relationship to diurnal variation of peak flow rate, improvement after bronchodilator, and airway calibre | Q36121113 | ||
| Differences in responsiveness to hyperventilation and methacholine in asthma and chronic bronchitis | Q36146203 | ||
| Does the outcome of the tidal breathing and dosimeter methods of assessing bronchial responsiveness in children with asthma depend on age? | Q36217459 | ||
| Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma | Q36472459 | ||
| Management of asthma: a consensus statement | Q38776464 | ||
| Regular inhaled beta-agonist treatment in bronchial asthma. | Q39513510 | ||
| Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. | Q40768651 | ||
| Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol | Q41175430 | ||
| Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. | Q53789780 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung disease | Q3392853 |
| asthma | Q35869 | ||
| P304 | page(s) | 547-554 | |
| P577 | publication date | 1992-09-01 | |
| P1433 | published in | The American Review of Respiratory Disease | Q26839505 |
| P1476 | title | Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group | |
| P478 | volume | 146 |
| Q74592079 | A comparative study of the effects of ketotifen, disodium cromoglycate, and beclomethasone dipropionate on bronchial mucosa and asthma symptoms in patients with atopic asthma |
| Q71955645 | A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease |
| Q43629981 | A comparison of the efficacy and safety of a half dose of fluticasone propionate with beclamethasone dipropionate and budesonide in childhood asthma |
| Q41559651 | A comparison of the efficacy and safety of inhaled corticosteroids in asthma |
| Q35755867 | A pilot study to enhance preventive asthma care among urban adolescents with asthma |
| Q32049879 | A review of budesonide inhalation suspension in the treatment of pediatric asthma |
| Q47563141 | AJRCCM: 100-Year Anniversary. Focus on Asthma in Children and Adults |
| Q35532986 | Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma |
| Q34567505 | Airway remodeling in the pathogenesis of asthma |
| Q33751283 | Airway wall remodelling: does it occur and what does it mean? |
| Q37522916 | An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice |
| Q37735203 | An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids |
| Q49485552 | Applicability of evidence from previous systematic reviews on immunotherapy in current practice of childhood asthma treatment: a GRADE (Grading of Recommendations Assessment, Development and Evaluation) systematic review |
| Q36825049 | Assessment of asthma control and its impact on optimal treatment strategy |
| Q92235540 | Asthma Disease Management Program |
| Q77461058 | Asthma in the emergency department |
| Q35649009 | Asthma management across the life span: applications for the adult and older adult |
| Q37247422 | Asthma management and prevention: current perspectives |
| Q40140026 | Asthma management and prevention: current perspectives |
| Q39575274 | Asthma symptoms, morbidity, and antiinflammatory use in inner-city children |
| Q53369314 | Asthma treatment in schoolchildren: lung function in different therapeutic groups. |
| Q94564218 | Asthma: A Loss of Post-natal Homeostatic Control of Airways Smooth Muscle With Regression Toward a Pre-natal State |
| Q45109090 | Asthma: benchmarking for quality improvement |
| Q41340900 | Asthma: from childhood to adulthood |
| Q33909166 | Beclomethasone for asthma in children: effects on linear growth |
| Q46733949 | Beclomethasone inhaler versus intravenous lidocaine in the prevention of postoperative airway and throat complaints: a randomized, controlled trial |
| Q35026180 | Beta 2-adrenoceptor agonist-mediated inhibition of human airway smooth muscle cell proliferation: importance of the duration of beta 2-adrenoceptor stimulation. |
| Q42417839 | Bronchodilators and bronchial hyperresponsiveness |
| Q34424877 | Budesonide for chronic asthma in children and adults |
| Q34112928 | Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders |
| Q51695280 | Case 3: assessment. Exercise-induced inspiratory laryngeal stridor. |
| Q26863351 | Childhood asthma: diagnosis and treatment |
| Q44130759 | Clinical and immunologic factors associated with the presence or absence of airways hyper-responsiveness in childhood asthma |
| Q39468637 | Clinical management of asthma in the 1990s. Current therapy and new directions. |
| Q41475601 | Clinical relevance of bronchial hyperresponsiveness |
| Q74621195 | Cold air inhalation and exercise-induced bronchoconstriction in relationship to metacholine bronchial responsiveness: different patterns in asthmatic children and children with other chronic lung diseases |
| Q42973500 | Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma |
| Q44387254 | Comparison of montelukast and budesonide on bronchial reactivity in subjects with mild-moderate persistent asthma |
| Q37932864 | Corticosteroids in respiratory diseases in children |
| Q50641770 | Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. |
| Q43783364 | Current controversies in asthma treatment. |
| Q41752101 | Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma |
| Q36869140 | Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). |
| Q40539217 | Development of pediatric pulmonology in the United Kingdom, Europe, and Australasia |
| Q34345371 | Do inhaled corticosteroids inhibit growth in children? |
| Q44388200 | Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial |
| Q74810191 | Early use of inhaled steroids in children with asthma |
| Q35532923 | Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma |
| Q43997780 | Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability |
| Q34567514 | Effects of inhaled corticosteroids on growth in asthmatic children |
| Q46694299 | Effects of inhaled corticosteroids on the consequences of asthma |
| Q40768834 | Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. |
| Q41728966 | Efficacy and safety of inhaled corticosteroids. New developments |
| Q35174218 | Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma |
| Q36751687 | Evidence based review on levosalbutamol |
| Q45304873 | Evolution of therapy for childhood asthma |
| Q40461043 | Evolving role of theophylline for treatment of chronic childhood asthma |
| Q34997195 | Exercise-induced bronchoconstriction in asthmatic children: a comparative systematic review of the available treatment options |
| Q34720407 | Exercise-induced bronchospasm in the elite athlete |
| Q45183030 | Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma |
| Q44016402 | Fluticasone inhibits the progression of allergen-induced structural airway changes |
| Q41004326 | Future of anti-inflammatory therapy in asthma |
| Q38628855 | Geographic variation in inhaled corticosteroid use for children with persistent asthma in Medicaid |
| Q74449900 | Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group |
| Q36340685 | Idealhalers or realhalers? A comparison of Diskus and Turbuhaler |
| Q77313315 | Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy |
| Q35878513 | Impact of inhaled corticosteroids and leukotriene receptor antagonists on airway remodeling |
| Q41475584 | Impact of treatment on bronchial hyperresponsiveness |
| Q36077352 | Indirect bronchial hyper-responsiveness: the coming of age of a specific group of bronchial challenges. |
| Q36577566 | Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group |
| Q35034104 | Inhaled Corticosteroids Adverse Events In Asthmatic Children: A Review. |
| Q33851527 | Inhaled and nasal corticosteroids: safety aspects |
| Q33860023 | Inhaled corticosteroid therapy in newly detected mild asthma |
| Q35135367 | Inhaled corticosteroids in childhood asthma: long-term effects on growth and adrenocortical function. |
| Q34995731 | Inhaled corticosteroids in childhood asthma: the story continues |
| Q24194850 | Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth |
| Q24197575 | Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth |
| Q38287834 | Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. |
| Q24194852 | Inhaled corticosteroids in children with persistent asthma: effects on growth |
| Q24234654 | Inhaled corticosteroids in children with persistent asthma: effects on growth |
| Q38287831 | Inhaled corticosteroids in children with persistent asthma: effects on growth. |
| Q34069565 | Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review |
| Q35537562 | Inhaled fluticasone in bronchiectasis: a 12 month study |
| Q74449849 | Inhaled steroids in children: risks versus rewards |
| Q33944522 | Interactions between corticosteroids and beta agonists |
| Q45014734 | Is bronchodilator response in 2-yr-old children associated with asthma risk factors? |
| Q35644751 | Is forced expiratory volume in one second the best measure of severity in childhood asthma? |
| Q52221296 | Large lungs after childhood asthma. A case-control study. |
| Q43220125 | Levosalbutamol vs racemic salbutamol in the treatment of acute exacerbation of asthma |
| Q34392656 | Long-acting inhaled beta(2)-agonist therapy in asthma |
| Q44173319 | Long-term outcomes in paediatric asthma |
| Q73435576 | Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma |
| Q92368103 | Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate |
| Q43650593 | Low domestic exposure to house dust mite allergens (Der p 1) is associated with a reduced non-specific bronchial hyper-responsiveness in mite-sensitized asthmatic subjects under optimal drug treatment |
| Q34342101 | Low dose inhaled corticosteroids and the prevention of death from asthma. |
| Q73991860 | Low-dose budesonide improves exercise-induced bronchospasm in schoolchildren |
| Q74215781 | Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma |
| Q50044860 | Methacholine bronchial provocation test in patients with asthma: serial measurements and clinical significance |
| Q44571212 | Minimizing attrition in a long-term clinical trial of pediatric asthma |
| Q28769235 | National Athletic Trainers' Association position statement: management of asthma in athletes. |
| Q43655195 | Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids |
| Q41693586 | Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children |
| Q33860037 | Once-daily inhaled corticosteroids in children with asthma: dry powder inhalers |
| Q43819600 | One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height |
| Q36890928 | Optical illusions from visual data analysis: example of the New Zealand asthma mortality epidemic |
| Q30579833 | Options for bronchodilation in children: can we rely on adult data? |
| Q37839763 | Paediatric asthma outpatient care by asthma nurse, paediatrician or general practitioner: randomised controlled trial with two-year follow-up. |
| Q35532935 | Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group |
| Q24678822 | Pharmacotherapy and airway remodelling in asthma? |
| Q38579908 | Pharmacotherapy for the treatment of asthma: current treatment options and future directions. |
| Q34300554 | Phenotype specific treatment of asthma in childhood |
| Q37129714 | Potential savings from increasing adherence to inhaled corticosteroid therapy in Medicaid-enrolled children |
| Q34205979 | Predictors of study completion and withdrawal in a randomized clinical trial of a pediatric diabetes adherence intervention |
| Q33821254 | Prognostic factors for the outcome of childhood asthma in adolescence |
| Q35718674 | Progress in the management of childhood asthma |
| Q47551010 | Randomized Trial of Interventions to Improve Childhood Asthma in Homes with Wood-burning Stoves |
| Q55519885 | Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. |
| Q34246831 | Risk factors for the persistence of respiratory symptoms in childhood asthma |
| Q33864418 | Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease". |
| Q35138776 | Role of budesonide as maintenance therapy for children with asthma |
| Q34523194 | Safety of inhaled corticosteroids in children |
| Q44474641 | Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis |
| Q48736327 | Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial |
| Q35117833 | Scientific respiratory symposium, paris june 2010 |
| Q39378031 | Simultaneous treatment of asthma and allergic rhinitis |
| Q79101082 | Sputum eosinophilia in cough‐variant asthma as a predictor of the subsequent development of classic asthma |
| Q41678381 | Steroid therapy in obstructive airway diseases |
| Q33835017 | Structural consequences of airway inflammation in asthma |
| Q41719837 | Sympathomimetic enantiomers and asthma |
| Q57072321 | The Childhood Asthma Management Program (CAMP) |
| Q37973265 | The actual role of sodium cromoglycate in the treatment of asthma--a critical review |
| Q35183553 | The assessment of childhood asthma |
| Q39481325 | The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology |
| Q40849767 | The down-side of early intervention with inhaled corticosteroids |
| Q41006016 | The effect of fluticasone propionate on respiratory syncytial virus-induced chemokine release by a human bronchial epithelial cell line |
| Q41113706 | The efficacy of inhaled disodium cromoglycate and glucocorticoids |
| Q43713633 | The inhaled Steroid Treatment as Regular Therapy in early asthma (START) study: rationale and design |
| Q41018882 | The practical impact of pharmacoeconomics on institutional managers |
| Q41151318 | The role of corticosteroids in respiratory diseases of children |
| Q35754077 | The use of inhaled corticosteroids for persistent asthma in infants and young children |
| Q47845672 | Towards improving the accuracy of diagnosing asthma in early childhood. |
| Q41722672 | Treatment of childhood asthma. Options and rationale for inhaled therapy |
| Q35544014 | Treatment of childhood asthma: how do the available options compare? |
| Q73640607 | Trends in hospital admissions for childhood asthma in Oslo, Norway, 1980-95 |
| Q37117289 | Update in pediatric lung disease 2007. |
| Q35274533 | Usefulness of monitoring lung function in asthma |
| Q35263316 | Validation of an asthma symptom diary for interventional studies |
| Q35183567 | Weighing the risks of treatment versus nontreatment in pediatric asthma |
| Q33860271 | Why does airway inflammation persist? Is it failure to treat early? |
| Q28275393 | Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Imm |
Search more.